
|Articles|February 1, 2003
OTCs stem pharm costs, but the jury's still out on long-term savings
The launch of OTC antihistamines helps plans cut costs, but skeptics argue that accessibility will suffer because of cost barriers
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilar denosumab could save $0.59 per member per month
2
Racial differences in treatment priorities highlight opportunity to strengthen shared decision-making in lung cancer care
3
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
4
Stanford scientists find link between Epstein-Barr virus and lupus
5






















































